Clovis Oncology, Inc. (CLVS) financial statements (2021 and earlier)

Company profile

Business Address 5500 FLATIRON PARKWAY
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments240297520564266529483
Cash and cash equivalents240162222464216279483
Short-term investments 13529810050250 
Receivables2721136012
Inventory, net of allowances, customer advances and progress billings31272728   
Inventory31272728   
Prepaid expense4442634
Other current assets91998785
Other undisclosed current assets   20 (1)(2)
Total current assets:311366572627279540491
Noncurrent Assets
Inventory, Noncurrent10498114    
Property, plant and equipment1215274453
Intangible assets, net (including goodwill)1291261158578161279
Goodwill63636365575966
Intangible assets, net (excluding goodwill)6663522021102213
Other noncurrent assets192323202813
Other undisclosed noncurrent assets304012    
Total noncurrent assets:29530329110885174295
TOTAL ASSETS:606670864735365713786
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities72749641302318
Accounts payable2732291511113
Accrued liabilities4542682619118
Employee-related liabilities      5
Taxes payable      0
Interest and dividends payable      2
Debt64      
Other undisclosed current liabilities49593040355330
Total current liabilities:18513312682667648
Noncurrent Liabilities
Long-term debt and lease obligation435645575282281  
Long-term debt, excluding current maturities435645575282281  
Liabilities, other than long-term debt, including:22164157119
Deferred revenue and credits411 
Deferred tax liabilities, net   3167
Business combination, contingent consideration, liability     2552
Other undisclosed liabilities, other than long-term debt2216    
Other undisclosed noncurrent liabilities14364  20280288
Total noncurrent liabilities:579711591286303337407
Total liabilities:764844717368368413455
Stockholders' equity
Stockholders' equity attributable to parent(159)(174)146368(4)301332
Common stock0000000
Additional paid in capital2,4982,1142,0341,8871,1751,130785
Accumulated other comprehensive loss(44)(45)(45)(42)(48)(47)(24)
Accumulated deficit(2,613)(2,244)(1,843)(1,477)(1,131)(782)(429)
Total stockholders' equity:(159)(174)146368(4)301332
TOTAL LIABILITIES AND EQUITY:606670864735365713786

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues16514395560  
Revenue, net560  
Cost of revenue
(Cost of Goods and Services Sold)
   (1)(0)  
Gross profit:16514395540  
Operating expenses(467)(520)(429)(293)(373)(377)(172)
Other undisclosed operating income   10 14
Operating loss:(302)(377)(334)(238)(373)(377)(158)
Nonoperating income (expense)(68)(22)(34)(112)(8)(5)1
Foreign currency transaction gain (loss), before tax(0)(1)(0)(0)(1)34
Other nonoperating income (expense)168410(0)
Interest and debt expense(35)18(3)(10)(8)(8)(3)
Loss from continuing operations before equity method investments, income taxes:(405)(380)(370)(360)(390)(390)(160)
Other undisclosed income (loss) from continuing operations before income taxes35(18)310883
Loss from continuing operations before income taxes:(370)(399)(367)(350)(381)(382)(158)
Income tax expense (benefit)1(2)(1)43229(2)
Net loss available to common stockholders, diluted:(369)(400)(368)(346)(349)(353)(160)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(369)(400)(368)(346)(349)(353)(160)
Other comprehensive income (loss)1(0)(2)5(0)(23)(29)
Comprehensive loss, net of tax, attributable to parent:(369)(401)(370)(341)(349)(376)(189)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: